Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Report Outlines how Pharmaceutical Industry is Adjusting the Management of Medical and Commercial Advisory Board Meetings


CHAPEL HILL, N.C., Nov. 10, 2017 /PRNewswire/ -- Pharmaceutical companies have long used advisory boards to gain commercial and medical insights about products both in development and already on the market.  

But new Sunshine Act reporting requirements have forced the pharma industry to adjust how it manages advisory board meetings. To highlight current practices in managing advisory boards, consulting leader Best Practices, LLC conducted a new study focused on key aspects of planning and executing advisory boards.

While 83 percent of companies said they conduct virtual advisory boards, participants said only about 21 percent of advisory board meetings, on average, are held virtually. Virtual ad boards have a different set of criteria such as saving on travel costs and gaining rapid feedback from participants, according to the study.

The study, "Best Practices in Managing Advisory Board Meetings in the Global Market," provides information on how pharma is currently approaching issues such as how many internal stakeholders attend meetings, how insights are gathered and distributed and to whom and the percentage of medical meetings versus commercial. The research shows how companies manage their various advisory boards, as well as provides critical metrics and insights into how organizations measure the success of their advisory boards.

For this study, Best Practices, LLC engaged 12 leaders at 12 pharmaceutical companies through a benchmarking survey instrument. Executive interviews also were conducted as part of the research. 

Topics addressed in this study include:

Pharmaceutical leaders, vice presidents, directors, managers and other executives involved with the planning of advisory board meetings can utilize this study to identify the top challenges, winning strategies and best practices for successfully conducting various advisory boards and utilizing the knowledge gathered from them.

Download a complimentary report summary at: http://www.best-in-class.com/rr1472.htm.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

 

SOURCE Best Practices, LLC


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: